Gubra tries to stand out by pairing lab services for drug developers with its own early drug ideas, which could bring in partner payments and reduce reliance on one line of work. But if biotech funding stays tight or new non-animal research tools win out, the company’s growth plan could wobble.Read more
Gubra sits at the crossroads of the obesity drug boom and a research-services business that benefits when drugmakers outsource more work, but both revenue streams can swing around based on partner trial progress and biotech funding. The big question is whether its early-stage pipeline and collaboration engine can smooth out that lumpiness—or whether delays and smaller-client demand keep results choppy.Read more
No trending discussion available.
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus’ FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
